Maintenance of B cells during chronic murine Trypanosoma brucei gambiense infection

African trypanosomosis is a debilitating parasitic disease occurring in large parts of sub‐Saharan Africa. Trypanosoma brucei gambiense accounts for 98% of the reported HAT infections and causes a chronic, gradually progressing disease. Multiple experimental murine models for trypanosomosis have demonstrated inflammation‐dependent apoptosis of splenic follicular B (FoB) cells and the destruction of B‐cell memory against previously encountered pathogens. Here, we report that during murine infection with a chronic T. b. gambiense field isolate, FoB cells are retained. This coincided with reduced levels of IFN‐γ and TNF‐α during the acute phase of the infection. This result suggests that in chronic infections with low virulent parasites, less inflammation is elicited and consequently no FoB cell destruction occurs.

[1]  B. Ryffel,et al.  IFN‐γ mediates early B‐cell loss in experimental African trypanosomosis , 2015, Parasite immunology.

[2]  L. Boon,et al.  NK-, NKT- and CD8-Derived IFNγ Drives Myeloid Cell Activation and Erythrophagocytosis, Resulting in Trypanosomosis-Associated Acute Anemia , 2015, PLoS pathogens.

[3]  S. Magez,et al.  Escape mechanisms of African trypanosomes: why trypanosomosis is keeping us awake , 2014, Parasitology.

[4]  M. Camara,et al.  Unravelling Human Trypanotolerance: IL8 is Associated with Infection Control whereas IL10 and TNFα Are Associated with Subsequent Disease Development , 2014, PLoS pathogens.

[5]  S. Magez,et al.  Antibody‐mediated control of Trypanosoma vivax infection fails in the absence of tumour necrosis factor , 2014, Parasite immunology.

[6]  S. Magez,et al.  Chronic Trypanosoma congolense infections in mice cause a sustained disruption of the B‐cell homeostasis in the bone marrow and spleen , 2014, Parasite immunology.

[7]  J. van Griensven,et al.  Gambiense Human African Trypanosomiasis and Immunological Memory: Effect on Phenotypic Lymphocyte Profiles and Humoral Immunity , 2014, PLoS pathogens.

[8]  L. Van Melderen,et al.  Complete Genome Sequence of the Escherichia coli PMV-1 Strain, a Model Extraintestinal Pathogenic E. coli Strain Used for Host-Pathogen Interaction Studies , 2013, Genome Announcements.

[9]  S. Magez,et al.  T. brucei Infection Reduces B Lymphopoiesis in Bone Marrow and Truncates Compensatory Splenic Lymphopoiesis through Transitional B-Cell Apoptosis , 2011, PLoS pathogens.

[10]  S. Magez,et al.  Acute Disruption of Bone Marrow B Lymphopoiesis and Apoptosis of Transitional and Marginal Zone B Cells in the Spleen following a Blood-Stage Plasmodium chabaudi Infection in Mice , 2011, Journal of parasitology research.

[11]  P. Kennedy,et al.  Focus–Specific Clinical Profiles in Human African Trypanosomiasis Caused by Trypanosoma brucei rhodesiense , 2010, PLoS neglected tropical diseases.

[12]  N. Biteau,et al.  Murine Models for Trypanosoma brucei gambiense Disease Progression—From Silent to Chronic Infections and Early Brain Tropism , 2009, PLoS neglected tropical diseases.

[13]  P. De Baetselier,et al.  The Role of B-cells and IgM Antibodies in Parasitemia, Anemia, and VSG Switching in Trypanosoma brucei–Infected Mice , 2008, PLoS pathogens.

[14]  S. Magez,et al.  Trypanosomiasis-Induced B Cell Apoptosis Results in Loss of Protective Anti-Parasite Antibody Responses and Abolishment of Vaccine-Induced Memory Responses , 2008, PLoS pathogens.

[15]  D. Nolan,et al.  Anti-Trypanosoma brucei activity in Cape buffalo serum during the cryptic phase of parasitemia is mediated by antibodies. , 2007, International journal for parasitology.

[16]  P. De Baetselier,et al.  A Glycosylphosphatidylinositol-Based Treatment Alleviates Trypanosomiasis-Associated Immunopathology1 , 2007, The Journal of Immunology.

[17]  C. Burri,et al.  Clinical aspects of 2541 patients with second stage human African trypanosomiasis. , 2006, Acta tropica.

[18]  P. De Baetselier,et al.  The Induction of a Type 1 Immune Response following a Trypanosoma brucei Infection Is MyD88 Dependent1 , 2005, The Journal of Immunology.

[19]  J. Sternberg.  Human African trypanosomiasis: clinical presentation and immune response , 2004, Parasite immunology.

[20]  P. De Baetselier,et al.  P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. , 2004, The Journal of infectious diseases.

[21]  D. Gouma,et al.  IL-10-Deficient Mice Demonstrate Multiple Organ Failure and Increased Mortality During Escherichia coli Peritonitis Despite an Accelerated Bacterial Clearance1 , 2001, The Journal of Immunology.

[22]  C. Burri,et al.  Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis , 2001, Tropical medicine & international health : TM & IH.

[23]  D. Al,et al.  Role of antibody in the elimination of trypanosomes after DL-alpha-difluoromethylornithine chemotherapy. , 1983 .

[24]  P. McCann,et al.  Role of antibody in the elimination of trypanosomes after DL-alpha-difluoromethylornithine chemotherapy. , 1983, The Journal of parasitology.

[25]  K. Esser,et al.  Trypanosoma rhodesiense infection in B-cell-deficient mice , 1977, Infection and immunity.

[26]  C. Clayton,et al.  Suppressor cells and loss of B-cell potential in mice infected with Trypanosoma brucei. , 1977, Clinical and experimental immunology.